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Abstract 
If people at risk of HIV infection are tested annually and started on treatment as soon as they are found to be 
HIV-positive it should be possible to reduce the case reproduction number for HIV to less than one, eliminate 
transmission and end the epidemic. If this is to be done it is essential to know if it would be affordable, and cost 
effective. Here we show that in all but eleven countries of the world it is affordable by those countries, that in 
these eleven countries it is affordable for the international community, and in all countries it is highly cost-
effective. 
Introduction 
The science behind Treatment-as-Prevention is 
clear.1 Annual testing and immediate ART can stop 
transmission2-7 and at the same time gives people 
infected with HIV the best prognosis.8-16 
Furthermore, a number of studies have shown that 
ART is cost-effective17-19 even in poorly resourced 
countries. Here we use data on the number of 
people living with HIV and the gross domestic 
product (GDP), for all countries, to explore the 
affordability, cost and cost-effectiveness of putting 
all HIV-positive people onto ART. 
Methods 
To estimate the affordability of ART we calculate, 
for each country in the world, an affordability 
index, AI, which is the cost of giving all HIV-
positive people ART expressed as a percentage of 
GDP. If the AI is greater than 2% we regard 
universal ART as unaffordable, between 1% and 
2% as marginal and less than 1% as affordable. To 
calculate the affordability if funding in resource 
limited countries is provided by the international 
community, we compare the cost of ART to current 
global spending on ART in lower and middle 
income countries. Since there is no universally 
agreed definition of affordability we also compare 
the cost of universal ART to the cost of spending 
on the military in each country. To estimate the 
cost-effectiveness we calculate the cost-
effectiveness ratio, CER, as the cost of maintaining 
one person on ART as a proportion of the per 
capita GDP. If the cost per life year saved is less 
then three times per capita GDP we regard it is 
cost-effective, if it is less than the per capita GDP 
we regard it as highly cost-effective.20 
 We use data on the number of people living 
with HIV for each country in the world from 
UNAIDS.21 We use data on the GDP from 
Knoema,22 on the per capita GDP from Wikipedia23 
and on military spending from The Guardian.24 
 We assume that the cost of maintaining one 
person on ART for one year is US$500: half for 
drugs and half for monitoring, care and support.25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Red and green bars, upper axis: affordability index, AI: 
the cost of universal ART as a percentage of GDP. Blue bars, 
lower axis: cumulative cost of universal ART. Shaded areas: AI 
5% to 8%, 2% to 5%, 1% to 2% and 0.1% to 1%. In all other 
countries the AI is less than 0.1%. Embedded numbers: military 
spending divided by the cost of universal ART. Red bars 
military spending greater than the cost of universal ART; green 
bars military spending less than the cost of universal ART. 
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Results 
In Figure 1 countries are ordered according to 
decreasing values of the AI. In Malawi, for 
example, the cost of maintaining all HIV-positive 
people on ART would amount to almost 8% of 
GDP which is unaffordable and the same holds for 
ten other countries for which the AI is greater than 
2%: Lesotho, Zimbabwe, Mozambique, Burundi, 
Uganda, the Central African Republic, Tanzania, 
Zambia, Swaziland and Kenya. These countries 
will need international assistance to finance 
universal ART. 
 In seven countries, Liberia, Togo, Rwanda, 
Sierra Leone, Cameroon, Chad and Guinea-Bissau, 
the AI is between 1% and 2% of GDP and they will 
also need international assistance. 
 For the remaining 18 countries the AI is less 
than 1% and they should be able to finance ART 
out of their own budgets although support for 
technical assistance may still be needed. For all of 
the countries not shown in Figure 1 the AI is less 
than 0.1% and these countries should be able to 
maintain all HIV-positive people on ART. 
 In 2009 a total of US$ 16 billion was available 
for the AIDS response in lower and middle income 
countries21 and the target is to increase this to US$ 
22 billion.26 The cumulative cost of universal ART 
is shown by the blue bars in Figure 1. For the first 
eleven countries for which international assistance 
is needed the total cost of universal ART is US$ 4.7 
billion per year or 29% of 2009 global expenditure 
on ART in middle and lower income countries.21 
For all the countries shown in Figure 1 the total 
cost is US$ 10.8 billion per year, or 68% of 2009 
global expenditure on ART in lower and middle 
income countries,27 US$ 4.4 billion, or 41% of this, 
is needed for Nigeria and South Africa alone. 
 Only two countries, Zimbabwe and Liberia, 
have a CER close to 1 (data not shown) so that 
Universal ART is highly cost-effective in even 
these two countries, while in the other countries 
shown in  Figure 1 the median CER is 0.33 (IQR: 
0.21−0.49; Max: 1.10; Min 0.03). 
 In Figure 1 the ratio of military spending to the 
cost of universal ART is given by the embedded 
numbers; where this ratio is less than 1 the bars are 
green, where it is greater than 1 the bars are red. In 
almost all of the countries where the cost of 
universal ART is less then 2% of GDP, current 
spending more on their military is greater than the 
cost of universal ART. The two most important 
countries in this regard are South Africa and 
Nigeria which, as noted above, account for 40% of 
the global cost of universal ART. However, as 
shown in Figure 1, the cost of universal ART in 
both Nigeria and South Africa is about 0.7% of 
GDP; in Nigeria this amounts to only 70% of 
current military spending and in South Africa to 
only 50% of current military spending. 
Conclusions 
In all but eleven countries universal ART should be 
affordable by the governments of those countries 
although support for technical assistance will still 
be needed. In the eleven countries in which 
universal ART is probably not affordable by their 
governments, the total cost of universal ART is 
only 29% of current global expenditure on HIV so 
that with international assistance universal ART is 
affordable in these countries as well. Even if the 
international community were to pay for ART in all 
those countries of the world where the AI is greater 
than 0.1% the total cost would only amount to 68% 
of current global expenditure on HIV and to 40% if 
we exclude Nigeria and South Africa. Since 
universal ART is highly cost-effective in every 
country in the world, based on the definition used 
by the World Health Organization,20 financial 
considerations should not deter the world from 
working towards universal ART. 
 Finally, it is worth noting that the cost of ART 
in the United States is one hundred times the cost of 
ART in middle and lower income countries. Even 
allowing for this the AI in the United States is 0.2% 
making it affordable. The CER is 0.5 making it 
highly cost effective but the total cost is US$ 30 
billion per year, one third more than the current 
spending on HIV in the United States of US$22 
billion.27 
 Universal ART is affordable, cost-effective and 
within current global funding commitments. Since 
universal ART would also stop transmission4 steps 
should be taken to start implementing universal 
ART as soon as possible. 
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